Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

被引：11

作者：

Brummendorf, Tim H. ^{[1
]}

Gambacorti-Passerini, Carlo ^{[2
]}

Hochhaus, Andreas ^{[3
]}

Lipton, Jeff H. ^{[4
]}

Kota, Vamsi ^{[5
]}

Deininger, Michael W. ^{[6
]}

Leip, Eric ^{[7
]}

Viqueira, Andrea ^{[8
]}

Ferdinand, Roxanne ^{[9
]}

Cortes, Jorge E. ^{[10
]}

机构：

[1] Univ Klinikum RWTH Aachen, Med Fac, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany

[2] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy

[3] Univ Klinikum Jena, Abt Hamatol & Internist Onkol, Klin Innere Med 2, Jena, Germany

[4] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Blood & Marrow Transplant Program, Toronto, ON, Canada

[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[6] Univ Utah, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[7] Pfizer Inc, Cambridge, MA USA

[8] Pfizer SLU, Madrid, Spain

[9] Pfizer Ltd, Walton On The Hill, England

[10] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1182/blood-2018-99-110543

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3005

引用

页数：4